title: Selection of the antifungal agent decides prognosis of invasive aspergillosis: case report of a successful outcome with voriconazole.
abstract: Invasive aspergillosis is a rare disease and is often misdiagnosed. The clinical course is quite aggressive and it is a potentially fatal disease. We report a case of invasive aspergillosis involving the dura mater and optic nerves which was successfully treated with voriconazole, even though the patient had residual monocular blindness. An 86-year-old Japanese man complained of developing loss of vision in his left eye while taking oral fluconazole prescribed by an otolaryngologist for mycosis of the left maxillary sinus. He was referred to our hospital. At the first visit, he already had no light perception in the left eye, with decreased ocular motility in all directions and orbital apex syndrome. His corrected distance visual acuity (CDVA) in the right eye was 20/25 with enlargement of Mariotte's blind spot. Magnetic resonance imaging revealed inflammation around both optic nerves that also involved the dura mater. His antifungal therapy was changed to intravenous voriconazole. Although his right CDVA temporarily declined to 20/50, it improved to 20/16 by 10 months after the initiation of treatment. Maxillary sinus biopsy detected Aspergillus. Invasive aspergillosis progresses rapidly and aggressively. The present case highlights the importance of early diagnosis and selection of an appropriate antifungal agent.
authors: Department of Ophthalmology, Saiseikai Kurihashi Hospital, 714-6, Koemon, Kuki-city, Saitama, 349-1105, Japan.
authors: Hisaya
authors: H
authors: Arakawa
authors: Chikako
authors: C
authors: Suto
authors: Hiroko
authors: H
authors: Notani
authors: Takashi
authors: T
authors: Ishida
authors: Kayoko
authors: K
authors: Abe
authors: Yasuo
authors: Y
authors: Ookubo
mesh_terms: D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009916:Orbital Diseases / Q000188:drug therapy* / Q000382:microbiology; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012852:Sinusitis / Q000382:microbiology*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole
references: Clin Infect Dis. 2008 Feb 1;46(3):327-60
references: 18177225
references: Surv Ophthalmol. 1996 Sep-Oct;41(2):142-54
references: 8890440
references: Ophthalmology. 2011 Sep;118(9):1886-91
references: 21665281
references: Lancet. 1995 Jan 7;345(8941):17-20
references: 7799700
references: Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):236-40
references: 12578456
references: J Laryngol Otol. 2003 Apr;117(4):280-5
references: 12816217
references: Br J Ophthalmol. 2004 May;88(5):681-7
references: 15090423
references: Auris Nasus Larynx. 2009 Apr;36(2):224-7
references: 18650040
references: N Engl J Med. 1997 Jul 24;337(4):254-9
references: 9227932